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WHIPPLE´S DISEASE WITH NEUROLOGICAL
MANIFESTATIONS
Case report
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ABSTRACT - Whipple´s disease (WD) is an uncommon multisystem condition caused by the bacillus Tropheryma whipplei. Central
nervous system involvement is a classical feature of the disease observed in 20 to 40% of the patients. We report the case of a 62
yeards old man with WD that developed neurological manifestations during its course, and discuss the most usual signs and symp-
toms focusing on recent diagnostic criteria and novel treatment regimens.
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Doença de Whipple com manifestações neurológicas: relato de caso
RESUMO - A doença de Whipple (DW) é distúrbio multissistêmico raro causado pelo bacilo Tropheryma whipplei. O envolvimento
do sistema nervoso central é um aspecto clássico da doença, sendo observado em 20 a 40% dos pacientes. Relatamos o caso de
homem de 62 anos com DW que desenvolveu manifestações neurológicas durante sua evolução, com o objetivo de discutir os sinais
e sintomas mais comuns e destacar os critérios diagnósticos e propostas terapêuticas mais recentes.
PALAVRAS-CHAVE: doença de Whipple, doença inflamatória intestinal, demência, polineuropatia
Whipple´s disease (WD) or intestinal lypodystrophy was first
described in 19071. It is a relatively rare multisystem disorder
caused by the gram-positive bacillus Tropheryma whipplei.The
usual presenting complaints include pronounced weight loss,
mal-absorptive diarrhea (sometimes accompanied by abdom-
inal cramping and bloody stool), recurrent non-deforming pol-
yarthritis and longstanding low grade fever2. Cutaneous hyper-
pigmentation and lymphadenopathy are also common clini-
cal signs. Central nervous system (CNS) involvement is a clas-
sical feature of WD observed in 20 to 40% of cases. CNS man-
ifestations are myriad and usually develop in later stages of
the illness3, often with cranial nerve and cognitive complaints.
Approximately 5% of the patients follow an unusual presen-
tation with isolated CNS symptoms4.
Available data on CNS WD are scant, consisting basically
of isolated case reports. Gerard et al.3 found only 122 reported
cases in the literature since 1960, most of them in Europe and
North America. To our knowledge, the following case is the
first to be reported in Brazil.
CASE
A 62-year-old white man, retired electrician, came to our
Gastroenterologic Clinic in 1989 complaining of increased stool fre-
quency and liquidity, associated with pronounced weight loss (20 Kg)
in the last 2 years. Subsequent investigation disclosed a mal-absorp-
tive syndrome, steatorrhoea and hepatosplenomegaly. Six months lat-
er, he developed bilateral knee arthritis which subsided spontaneous-
ly in two weeks. In 1990, an upper digestive endoscopy combined
with multiple gastric and duodenal biopsies was performed. Histologic
examination of the bowel specimens revealed flattened villi, small
intestinal mucosa laden with distended foamy macrophages in the
lamina propria and intracellular periodic acid Schiff (PAS) positive gran-
ules (Figure 1A - 1B). Acid-fast bacilli were not identified in Ziehl-
Neelsen stain. Electron microscopy promptly identified the causative
agent and Whipple´s disease was then confirmed (Figure 1C - 1D).
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Sulfamethoxazole-trimethoprim (SMZ-TMP) double dose (160 mg/800
mg) was started, with excellent response.Abdominal symptoms com-
pletely disappeared and he recovered weight. In 1992, treatment was
interrupted.
Three years later, he presented with erectile dysfunction and lab
tests showed hyperprolactinemia (87.6ng/ml) and low testosterone
levels (13.7 pg/ml). Cranial computed tomography (CT) had no abnor-
mal findings. Bromocriptine 2.5 mg/day was introduced leading to
incomplete relief. In 1995, the patient developed progressive diplop-
ia, gait disturbance, sensitive complaints and intense retro-ocular
pain. Neurological examination showed an axial and left-sided cere-
bellar ataxia, accompanied by slow voluntary vertical saccades with
diminished abduction of the left eye.Tactile and painful sensation  were
also impaired in the right side of the body, but no pyramidal or cog-
nitive deficits were found. Cerebrospinal fluid (CSF) showed pleocy-
tosis with lymphocyte predominance (55cells/mm3) and 2 PAS-posi-
tive cells. Serum folate and vitamin B12, thyroid function tests, anti-
nuclear antibody titers,Venereal Disease Research Laboratory (VDRL)
and human immunodeficiency virus (HIV) tests were all negative.
Seven days after this first evaluation, lethargy and drowsiness devel-
oped. Another lumbar puncture was performed and CSF analysis
revealed 2986 cells/mm3 (84% neutrophils), with increase in protein
concentration (215 mg/dl) and slight decrease in glucose concentra-
tion. Gram´s stain, bacterial counterimmunoelectrophoresis and cul-
tures were all negative. Ceftriaxone 1g b.i.d. was given for 14 days
and there was marked improvement in the level of consciousness. Four
weeks later, CSF analysis was normal and magnetic ressonance imag-
ing (MRI) findings revealed bilateral ovoid images in the lentiform nuclei,
with neighboring T1 hyperintense and FLAIR hypointense lesions,
without contrast enhancement (Figure 2A - 2B).The patient was then
discharged taking again SMZ-TMP.
Over the next few months, ophthalmoparesis worsened, result-
ing in complete loss of voluntary vertical eye movements associat-
ed to medial deviation of the left ocular globe (left abducent nerve
palsy). Vergence nystagmoid jerks of both eyes, which were syn-
chronous with a soft chin tremor, soon developed, consistent with
oculomasticatory myorhythmia (OMM).Additionally, primitive reflex-
es (such as snout, sucking, and palmomental) began to be noticed.
There were no changes in clinical or neurological features until 2001,
when depressive and amnestic complaints appeared.
At present (March 2003), besides cerebellar ataxia, he has signs
of polyneuropathy (abolished Achillean reflexes and decreased vibra-
tory sensation in the feet). Neuropsychological and neuropsychiatric
assessment using CAMCOG/CAMDEX batteries reveals slight depres-
Fig 1. A - Small intestinal mucosa showing numerous macrophages with clear foamy cytoplasm in the lamina pro-
pria (HE, x 400). B - Some macrophages have slightly PAS positive cytoplasm (PAS, x 400). C - Electron micro-
graph showing a macrophage. The nucleus is in the upper left corner. The cytoplasm contains amorphous mate-
rial and a small cluster of bacilli (arrow) (x 3600). D - Detail of bacilli in the cytoplasm of another cell. The bacilli
appear homogeneously electron dense with double layered external wall (x 20000).
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sive symptoms and mild dementia, with poor recall of 6 figures and
5 other items after a few minutes, impairment of constructional
praxis and arithmetic calculation, but preserved time/place orienta-
tion and basic language skills (except dysarthria and rare word find-
ing difficulties, without anomia). Single-photon emission computed
tomography of the brain (99mTc ECD SPECT) shows diffuse and het-
erogeneous cortical hypoperfusion.The patient now takes SMZ-TMP,
bromocriptine and fluoxetine on a regular basis. He keeps walking
unassisted, without major functional limitations, and his cognitive
deficits have not significantly progressed.
DISCUSSION
WD usually affects caucasian middle-aged individuals (mean
age at diagnosis around 50 years) and is about 8 times more
frequent in men. Recent epidemiological studies, including sev-
eral familial cases, point to an apparent genetic conditioned
susceptibility related to some HLA loci2. This last finding stron-
gly suggests that a host factor (defective T-helper cells of type
1 immunity) plays a key role in pathogenic events.Systemic man-
ifestations are generally the presenting features of WD.Abdominal
complaints, recurrent arthropathy and longstanding fever are
particularly common and precede diagnosis for a few years.
However, any organ can be involved and there are reports of
myocarditis/endocarditis5,6, polyserositis2, hepatosplenomegaly2
and uveitis7.According to Louis et al.8, around 80% of CNS WD
patients have systemic signs or symptoms at diagnosis.Therefore,
in the appropriate clinical setting, considering WD in a patient
with neurological deficits can be important.
CNS involvement was first described in 19589 and much
knowledge has emerged since then. Classical neuropatholog-
ical features include generalized cerebral atrophy and dif-
fusely scattered small chalky nodules in cortical and subependy-
mal gray matter. In fact, these nodules are true granulomas
that contain PAS-positive foamy macrophages and reactive
astrocytes. Areas of intense demyelination (resembling mul-
tiple sclerosis) and microinfarcts are also sometimes identi-
fied in tissue specimens10.
Our patient first presented neurological manifestations
two years after SMZ-TMP withdrawal. Such relapses of WD were
frequently reported when initial antibiotic treatment had not
been adequate and frequently included cerebral manifestations.
Short-term use of SMZ-TMP or tetracycline (which does not
cross the blood-brain barrier) were particularly related to CNS
relapses11,12 and a worse clinical course. Feldman et al.13 report-
ed a patient disclosing  acute meningoencephalitis during a
relapse of the disease whose abnormalities closely recalled our
own patient.
There are still conflicting data related to the real preva-
lence of neurological signs and symptoms in WD. Recent
review articles3,8 suggest that almost half of WD patients have
indeed evidence of CNS dysfunction. These manifestations
are quite diverse and traditionally include OMM, cognitive
changes, voluntary gaze abnormalities, pyramidal signs, sen-
sory deficits, hypothalamic manifestations, cranial nerve abnor-
malities, ataxia and seizures. Besides such clinical variability,
some patterns of presentation should clearly point to the
diagnosis. One example is the classic triad of dementia,
supranuclear ophthalmoparesis and myoclonus, which is
observed in roughly 10% of cases. In this regard, OMM has
not been described in any other neurological disturbance to
date and therefore could be considered pathognomonic of CNS
WD. It occurs in 20% of cases and consists in the synchronous
coupling of rhythmic contractions of masticatory muscles and
the pendular vergence oscillations of both eyes at a slow rate
(1-2Hz). This unique sign of WD seems to be caused by brain
stem lesioning and somewhat resembles segmental spinal
myoclonus14.
Cognitive changes are perhaps the most common neuro-
logical abnormalities in WD (71% of cases) and generally
show incomplete response to the treatment. They tend to
progress insidiously and are usually accompanied by depres-
sion, personality and behavioral changes. Previous reports
Fig 2. T1-weighted MRI showing bilateral ovoid  lesions in the lentiform nuclei,
with slightly hypointense center and surrounding hyperintensity. A) coronal
view. B) axial view.
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identified disabling impairment in the domains of sustained
attention, memory, executive function and constructional prax-
is15.At later stages, these deficits completely fulfill criteria for
dementia (much like Alzheimer´s disease) and steadily wors-
en prognosis.
Voluntary gaze abnormalities preferentially affect vertical
movements of the eyes and are noticed in half of the patients.
There is usually progressive slowing of upward saccades, soon
followed by downward saccades. Some affected individuals
become virtually unable to look up or down at last and may
receive a diagnosis of progressive supranuclear palsy (PSP).
Isolated horizontal supranuclear gaze palsy is extremely
uncommon, but combined impairment in both directions (hor-
izontal and vertical) is frequently seen8. It is also interesting
that all cases presenting OMM had vertical supranuclear pal-
sy.
Internuclear ophthalmoplegia, pupillary abnormalities and
ptosis have been described in isolated WD patients. Oculomotor
(III), trochlear (IV) and abducens (VI) palsies are not usual
either, but reported in at least 5% of affected individuals7.
Together, cranial nerve abnormalities occur in 25% of cases.
Hypothalamic involvement has been clearly identified in pre-
vious papers16-18. Sleep/arousal disturbances, hyperphagia and
polydipsia were reported in 31% of cases.
Similarly, endocrine deficits related to hypopituitarism
were recognized in the setting of CNS WD19. These patients
presented with signs of hypothyroidism, complaints of erec-
tile dysfunction (just like our case) or galactorrhoea and had good
response to antimicrobial and hormonal replacement therapy.
Pyramidal and sensation deficits are other signs of CNS
derangement recorded in WD, just as myoclonus and seizures,
which are noticed in almost one fourth of patients.Additionally,
gait and stance instability related to cerebellar damage occur
in 20% of patients, being a major source of functional impair-
ment8. A few cases presenting with rapidly evolving cranial
hypertension were reported, most of them caused by tumor-
like lesions or acute hydrocephalus (Sylvius aqueduct steno-
sis)3,11. Various forms of peripheral neuropathy have been ob-
served as in other chronic inflammatory bowel diseases, prob-
ably associated to malabsorptive nutritional deficiencies20.
Conversely, spinal cord3,21 and muscle3 involvement are exceed-
ingly uncommon.
Once suspected, WD has been classically confirmed by
intestinal biopsy and histopathological analysis (PAS staining
and EM) in at least 80% of affected individuals. Particularly
in CNS WD, it is accurate in 70% of cases even if there are no
abdominal complaints. Hence, patients with neurological defi-
cits compatible with WD should initially have an upper diges-
tive endoscopy and duodenal biopsy. Recently, polymerase
chain-reaction (PCR) has been used to confirm the diagnosis
of WD2. This is emerging as a promising technique with high-
er sensibility and specificity22. Positive results of PCR assays
against Tropheryma whipplei have been obtained from sever-
al tissues, including brain and CSF23. Therefore, PCR will prob-
ably become an interesting tool for WD diagnosis (particular-
ly for CNS restricted disease) and long-term follow up.Microbial
cultures and serology are of little diagnostic help yet.
Neuroimaging and CSF analysis are usually undertaken and
can be diagnostically useful. Brain MRI findings in WD are large-
ly non-specific24. Lesions tend to affect in decreasing order of
frequency, cerebral frontal cortex, basal ganglia, periventric-
ular white matter, hypothalamus, temporal and parietal cor-
tex3. Similarly, CSF non-specific abnormalities have been iden-
tified in at least half of patients8. Most had slight CSF protein
elevation, lymphocyte pleocytosis and PAS-positive cells.
Nevertheless, some authors report acute meningitic presen-
tations with marked pleocytosis with polymorphonuclear pre-
dominance25,26.
Diagnostic guidelines based on available data were ulti-
mately proposed by Louis et al.8.These authors considered the
diagnosis of CNS WD definite in patients having at least one
of the following criteria: 1. OMM; 2.positive tissue biopsy
(PAS-positive cells); 3. positive PCR analysis.Additionally, if his-
tological or PCR analysis were not performed on CNS tissue,
then the patient must also demonstrate compatible neurolog-
ical signs (supranuclear vertical gaze palsy, rhythmic myoclonus,
dementia or hypothalamic manifestations). Our patient clear-
ly matches these criteria, having laboratory and clinical evi-
dence of CNS WD.
In the past, several antibiotic regimens were used for WD
without convincing results. The proper choice of an effective
drug is now recognized as an essential part of the treatment,
lessening the risks for future CNS relapses27,28. Oral SMZ-TMP
(160mg/800mg bid) is the currently recommended long-term
therapy and should be prescribed for at least one year2,29. In
addition, a 2-week course of parenteral therapy consisting of
ceftriaxone 2g/day is strongly suggested in severely ill patients
and must precede maintenance therapeutics. Alternative
approaches using penicillin plus streptomycin or minocycline
have been used on an individual basis and can be applied in
cases of sulfonamide intolerance.
These directions led to a lower rate of clinical relapses and
a much better long-term outcome. SMZ-TMP was particularly
effective for CNS WD patients, improving or at least stabiliz-
ing their course3. Nevertheless, the precise duration of antimi-
crobial treatment and the best follow-up approach must still
be determined. In some resistant cases, therapy is still a chal-
lenge but recent reports2 on the use of supportive gamma
interferon seem very promising.
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